OncRef

Clinical Trial: NCT06691984

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Amgen
Information Provided By:Amgen
Last Update Posted:2026-05-15

Study Overview

Brief Summary

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).

Official Title

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

Conditions

Metastatic Castration-resistant Prostate Cancer

Intervention / Treatment

  • Drug: Xaluritamig
  • Drug: Abiraterone
  • Drug: Enzalutamide
  • Drug: Cabazitaxel

Other Study ID Numbers

  • 20230005
  • 2024-513968-25

Start Date (Actual)

2024-12-09

Primary Completion Date (Estimated)

2029-01-02

Study Completion Date (Estimated)

2029-07-30

Enrollment (Actual)

707

Study Type

Interventional

Phase

Phase 3